Key facts
- This page summarizes Christopher Benecchi's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Nov 2024, 16:42.
Christopher Benecchi - 01 Nov 2024 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- SAGE
- Reported as of
- 01 Nov 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Nov 2024, 16:42:58 UTC
- Prior SEC filing
- 07 Aug 2024
- Next SEC filing
- 21 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- Greg Shiferman, attorney in fact for BENECCHI CHRISTOPHER
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Benecchi filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 14 Nov 2024.
Change
- Previous filing in this sequence was filed on 07 Aug 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SAGE
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +6,250
- Change %
- +34%
- Price
- $0.000000
- Shares after
- 24,737
- Date
- 01 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SAGE
transaction
Derivative
Stock Option (Right to buy)
Award
- Transaction value
- $0
- Shares
- +12,500
- Change %
- Price
- $0.000000
- Shares after
- 12,500
- Date
- 01 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,500
- Exercise price
- $6.05
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Consists of shares of common stock issuable under 6,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on November 1, 2025, subject to the Reporting Person's continued service.
Footnote F2
The option was granted on November 1, 2024 pursuant to the Plan. The shares underlying the option vest over four years, with 25% of the shares vesting on November 1, 2025, and the remainder vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service.